keyword
MENU ▼
Read by QxMD icon Read
search

Eliquis

keyword
https://www.readbyqxmd.com/read/28439702/a-comparison-of-apixaban-and-dabigatran-etexilate-for-thromboprophylaxis-following-hip-and-knee-replacement-surgery
#1
Adriane Mayer, Philipp Schuster, Bernd Fink
INTRODUCTION: Patients who have undergone hip or knee replacement surgery are exposed to a high risk of developing a post-operative venous thromboembolus and so have a need for an effective, medication-based, thrombosis prophylaxis. New orally active anticoagulants have been available for a few years now. These specific substances directly block either thrombin (e.g., dabigatran etexilate) or Factor Xa (e.g., apixaban). It is not clear whether there are any efficacy differences between these two substances because there have never been any head-to-head studies carried out...
April 24, 2017: Archives of Orthopaedic and Trauma Surgery
https://www.readbyqxmd.com/read/28381919/can-a-short-video-improve-apixaban-knowledge-in-an-inpatient-setting
#2
Christopher Giuliano, Thomas Nofar, Stephanie B Edwin
PURPOSE: To increase patient knowledge about apixaban (Eliquis, Bristol-Myers Squibb) using an educational video delivered in an urban inpatient setting. METHODS: This prospective, quasi-experimental study evaluated knowledge gain and retention in patients receiving apixaban after viewing a short educational video. Knowledge was assessed with a questionnaire immediately before, immediately after, and one month following the educational video. RESULTS: After 33 patients watched the video, scores increased by 19...
April 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28279251/oral-anticoagulants-for-primary-prevention-treatment-and-secondary-prevention-of-venous-thromboembolic-disease-and-for-prevention-of-stroke-in-atrial-fibrillation-systematic-review-network-meta-analysis-and-cost-effectiveness-analysis
#3
Jonathan Ac Sterne, Pritesh N Bodalia, Peter A Bryden, Philippa A Davies, Jose A López-López, George N Okoli, Howard Hz Thom, Deborah M Caldwell, Sofia Dias, Diane Eaton, Julian Pt Higgins, Will Hollingworth, Chris Salisbury, Jelena Savović, Reecha Sofat, Annya Stephens-Boal, Nicky J Welton, Aroon D Hingorani
BACKGROUND: Warfarin is effective for stroke prevention in atrial fibrillation (AF), but anticoagulation is underused in clinical care. The risk of venous thromboembolic disease during hospitalisation can be reduced by low-molecular-weight heparin (LMWH): warfarin is the most frequently prescribed anticoagulant for treatment and secondary prevention of venous thromboembolism (VTE). Warfarin-related bleeding is a major reason for hospitalisation for adverse drug effects. Warfarin is cheap but therapeutic monitoring increases treatment costs...
March 2017: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/28008269/perioperative-management-of-direct-oral-anticoagulants-doacs-a-systemic-review
#4
REVIEW
Tagore Sunkara, Emmanuel Ofori, Vadim Zarubin, Megan E Caughey, Vinaya Gaduputi, Madhavi Reddy
Direct oral anticoagulants (DOACs) are in wide use among patients requiring both short- and long-term anticoagulation, mainly due to their ease of use and the lack of monitoring requirements. With growing use of DOACs, it is imperative that physicians be able to manage patients on these medications, especially in the perioperative period. We aim to provide guidance on the management of DOACs in the perioperative period. In this review, we performed an extensive literature search summarizing the management of patients on direct-acting anticoagulants in the perioperative period...
2016: Health Services Insights
https://www.readbyqxmd.com/read/27984753/validated-spectrofluorimetric-methods-for-the-determination-of-apixaban-and-tirofiban-hydrochloride-in-pharmaceutical-formulations
#5
Ramzia I El-Bagary, Ehab F Elkady, Naira A Farid, Nadia F Youssef
Apixaban and Tirofiban Hydrochloride are low molecular weight anticoagulants. The two drugs exhibit native fluorescence that allow the development of simple and valid spectrofluorimetric methods for the determination of Apixaban at λ ex/λ em=284/450nm and tirofiban HCl at λ ex/λ em=227/300nm in aqueous media. Different experimental parameters affecting fluorescence intensities were carefully studied and optimized. The fluorescence intensity-concentration plots were linear over the ranges of 0.2-6μgml(-1) for apixaban and 0...
March 5, 2017: Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy
https://www.readbyqxmd.com/read/27013144/novel-oral-anticoagulants-in-plastic-surgery
#6
REVIEW
C F Munson, A J Reid
Novel oral anticoagulants (NOACs) have emerged as a good alternative to warfarin in the prevention of stroke for patients with atrial fibrillation. NOAC use is increasing rapidly; therefore, greater understanding of their use in the perioperative period is important for optimal care. Studies and reviews that reported on the use of NOACs were identified, with particular focus on the perioperative period. PubMed was searched for relevant articles published between January 2000 and August 2015. The inevitable rise in the use of NOACs such as rivaroxaban (Xarelto™), apixaban (Eliquis™), edoxaban (Lixiana™) and dabigatran (Pradaxa™) may present a simplified approach to perioperative anticoagulant management due to fewer drug interactions, rapidity of onset of action and relatively short half-lives...
May 2016: Journal of Plastic, Reconstructive & Aesthetic Surgery: JPRAS
https://www.readbyqxmd.com/read/26417627/apixaban-eliquis-in-deep-vein-thrombosis-and-pulmonary-embolism-warfarin-remains-the-standard-therapy
#7
(no author information available yet)
Not more effective than warfarin. The lower incidence of bleeding observed among patients selected for these trials must be weighed against the lack of either an antidote or a routine clotting test.
September 2015: Prescrire International
https://www.readbyqxmd.com/read/26369819/development-of-trypsin-like-serine-protease-inhibitors-as-therapeutic-agents-opportunities-challenges-and-their-unique-structure-based-rationales
#8
REVIEW
Guyan Liang, J Phillip Bowen
There has been a revolution in the development of effective, small-molecule anticoagulants and antiplatelet agents. Numerous trypsin-like serine proteases have been under active pursuit as therapeutic targets. Important examples include thrombin, factor VIIa, factor Xa, and β-tryptase with indications ranging from thrombosis and inflammation to asthma and chronic obstructive pulmonary disease (COPD). Trypsin-like serine proteases exhibit a highly similar tertiary folding pattern, especially for the region near the substrate binding pocket that includes the conserved catalytic triad consisting of histidine 57, aspartic acid 102, and serine 195...
2016: Current Topics in Medicinal Chemistry
https://www.readbyqxmd.com/read/26298448/an-observational-study-of-the-factor-xa-inhibitors-rivaroxaban-and-apixaban-as-reported-to-eight-poison-centers
#9
Henry A Spiller, James B Mowry, Alfred Aleguas, Jill R K Griffith, Robert Goetz, Mark L Ryan, Stacey Bangh, Wendy Klein-Schwartz, Scott Schaeffer, Marcel J Casavant
STUDY OBJECTIVE: Rivaroxaban and apixaban are part of a new group of oral anticoagulants targeting factor Xa and approved by the Food and Drug Administration in 2011 and 2012. These oral anticoagulants are administered at fixed daily doses, without the need for laboratory-guided adjustments. There are limited data available on supratherapeutic doses or overdose of the oral Xa inhibitors. This study characterizes the clinical effect in patients exposed to rivaroxaban and apixaban. METHODS: A retrospective study collected data from 8 regional poison centers covering 9 states...
February 2016: Annals of Emergency Medicine
https://www.readbyqxmd.com/read/26095540/direct-acting-oral-anticoagulants-pharmacology-indications-management-and-future-perspectives
#10
REVIEW
Antonio Gómez-Outes, Ma Luisa Suárez-Gea, Ramón Lecumberri, Ana Isabel Terleira-Fernández, Emilio Vargas-Castrillón
In recent years, several direct-acting oral anticoagulants (DOAC) have become available for use in Europe and other regions in indications related to prophylaxis and treatment of venous and arterial thromboembolism. They include the oral direct thrombin inhibitor dabigatran etexilate (Pradaxa, Boehringer Ingelheim) and the oral direct FXa inhibitors rivaroxaban (Xarelto, Bayer HealthCare), apixaban (Eliquis, Bristol-Myers Squibb), and edoxaban (Lixiana/Savaysa, Daiichi-Sankyo). The new compounds have a predictable dose response and few drug-drug interactions (unlike vitamin k antagonists), and they do not require parenteral administration (unlike heparins)...
November 2015: European Journal of Haematology
https://www.readbyqxmd.com/read/25746754/-center-punch-and-whole-spot-bioanalysis-of-apixaban-in-human-dried-blood-spot-samples-by-uhplc-ms-ms
#11
Naiyu Zheng, Long Yuan, Qin C Ji, Heidi Mangus, Yan Song, Charles Frost, Jianing Zeng, Anne-Françoise Aubry, Mark E Arnold
Apixaban (Eliquis™) was developed by Bristol-Myers Squibb (BMS) and Pfizer to use as an antithrombotic/anticoagulant agent and has been recently approved for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. A clinical study of apixaban, sponsored by BMS and Pfizer, included a pilot exploratory portion to evaluate the potential for future drug concentration monitoring using dried blood spot (DBS) sample collection. For DBS sample collection, a fixed blood volume was dispensed onto a DBS card by either regular volumetric pipette (venous blood collection) or capillary dispenser (finger prick blood collection)...
April 15, 2015: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
https://www.readbyqxmd.com/read/25682082/the-new-or-non-vitamin-k-antagonist-oral-anticoagulants-what-have-we-learned-since-their-debut
#12
REVIEW
Brandon J McMahon, Hau C Kwaan
One of the major advances in the management of thrombosis is arguably the introduction of the new non-vitamin K antagonist oral anticoagulants (NOACs). These are small molecules, designed to directly inhibit specific steps in the coagulation pathway, with dabigatran (Pradaxa), inhibiting thrombin and rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Lixiana), and betrixaban being factor Xa inhibitors. They have several advantages over vitamin K antagonists such as warfarin, with more predictable bioavailability, fewer drug interactions, and improved safety, especially intracranial hemorrhage...
March 2015: Seminars in Thrombosis and Hemostasis
https://www.readbyqxmd.com/read/25600045/-extended-options-of-anticoagulant-treatment-in-thromboembolism
#13
Debora Karetová, Jan Bultas
Thromboembolic disease (TD) is a relatively common disease with acute risk of death and potential long-term consequences in term of postthrombotic syndrome or chronic pulmonary hypertension. Anticoagulant therapy is the basic therapeutic procedure; thrombolytic therapy and the introduction cava filter are appropriately indicated for individual cases. In past few years, new direct oral anticoagulant drugs (NOAC) have occurred - Xa factor or thrombin inhibitors which have demonstrated the same efficacy and even higher safety in comparison to conventional treatment...
November 2014: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/25322783/lc-ms-ms-determination-of-apixaban-bms-562247-and-its-major-metabolite-in-human-plasma-an-application-of-polarity-switching-and-monolithic-hplc-column
#14
Janice Pursley, Jim X Shen, Alan Schuster, Oanh T Dang, Jim Lehman, Michael H Buonarati, Yan Song, Anne-Francoise Aubry, Mark E Arnold
BACKGROUND: apixaban (BMS-562247) (Eliquis(®)) is a novel, orally active, selective, direct, reversible inhibitor of the coagulation factor Xa (FXa). A sensitive and reliable method was developed and validated for the measurement of apixaban (BMS-562247) and its major circulating metabolite (BMS-730823) in human citrated plasma for use in clinical testing. METHODOLOGY/RESULTS: A 0.100 ml portion of citrated plasma sample was extracted and analyzed by LC-MS/MS. Run times were approximately 3 min...
August 2014: Bioanalysis
https://www.readbyqxmd.com/read/25219865/current-developments-for-the-oral-delivery-of-heparin
#15
REVIEW
Anna Schlüter, Alf Lamprecht
Anticoagulant therapy is widely used for the treatment and prophylaxis of deep vein thrombosis and coronary syndromes. Until now, drugs such as unfractionated heparin and low molecular weight heparins need to be administered parenterally. Parenteral administration results in lower patient compliance compared to oral therapy and for this reason, the focus of various research groups is to develop an oral heparin formulation which is as effective as the parenteral formulation, easy to use and non-toxic. In the last few years, some new oral anticoagulants like Rivaroxaban (Xarelto(®)), Apixaban (Eliquis(®)) and Dabigatranetexilat (Pradaxa(®)) have reached the market, but their use is limited to certain indications...
2014: Current Pharmaceutical Biotechnology
https://www.readbyqxmd.com/read/25195485/dental-implications-of-new-oral-anticoagulants-for-atrial-fibrillation
#16
Claire Curtin, Jamie M Hayes, Jeremy Hayes
UNLABELLED: As dental professionals, we should all be familiar with the most common oral anticoagulant, warfarin, and how to manage our patients that are taking it. However, several new oral anticoagulants which have recently been approved by the National Institute for Health and Care Excellence (NICE) are now being prescribed for patients in the United Kingdom. These new oral anticoagulants fall into two different categories: a direct thrombin inhibitor dabigatran etexilate (Pradaxa Boehringer-Ingelheim, Bracknell, Berkshire) and activated Factor X inhibitors rivaroxaban (Xarelto Bayer HealthCare, Newbury, Berkshire) and apixaban (Eliquis Bristol-Myers Squibb, Uxbridge, Middlesex)...
July 2014: Dental Update
https://www.readbyqxmd.com/read/24951330/orally-bioavailable-factor-xa-inhibitors-containing-alpha-substituted-gem-dimethyl-p4-moieties
#17
Michael J Orwat, Jennifer X Qiao, Kan He, Alan R Rendina, Joseph M Luettgen, Karen A Rossi, Baomin Xin, Robert M Knabb, Ruth R Wexler, Patrick Y S Lam, Donald J P Pinto
In an effort to identify a potential back-up to apixaban (Eliquis®), we explored a series of diversified P4 moieties. Several analogs with substituted gem-dimethyl moieties replacing the terminal lactam of apixaban were identified which demonstrated potent FXa binding affinity (FXa Ki), good human plasma anticoagulant activity (PT EC2x), cell permeability, and oral bioavailability.
August 1, 2014: Bioorganic & Medicinal Chemistry Letters
https://www.readbyqxmd.com/read/24784127/apixaban-eliquis-for-stroke-prevention-in-atrial-fibrillation
#18
Robert A Beck, William M King
No abstract text is available yet for this article.
April 15, 2014: American Family Physician
https://www.readbyqxmd.com/read/24777590/perioperative-management-of-patients-on-new-oral-anticoagulants
#19
A Lai, N Davidson, S W Galloway, J Thachil
BACKGROUND: New oral anticoagulants (NOACs) offer an alternative to warfarin for preventing stroke in patients with atrial fibrillation. NOACs are expected to replace warfarin and other vitamin K antagonists for most of their indications in the future. Knowledge of the use of NOACs in the perioperative period is important for optimal care. METHODS: Studies that reported on the use of NOACs were identified, focusing on evidence-based guidance relating to the perioperative period...
June 2014: British Journal of Surgery
https://www.readbyqxmd.com/read/24716468/new-oral-anticoagulants-clinical-indications-monitoring-and-treatment-of-acute-bleeding-complications
#20
REVIEW
C Fenger-Eriksen, A-M Münster, E L Grove
New oral anticoagulants like the direct thrombin inhibitor, dabigatran (Pradaxa®), and factor Xa-inhibitors, rivaroxaban (Xarelto®) and apixaban (Eliquis®) are available for prophylaxis and treatment of thromboembolic disease. They are emerging alternatives to warfarin and provide equal or better clinical outcome together with reduced need for routine monitoring. Methods for measuring drug concentrations are available, although a correlation between plasma drug concentrations and the risk of bleeding has not been firmly established...
July 2014: Acta Anaesthesiologica Scandinavica
keyword
keyword
10668
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"